Industry Updates for the Psychedelics World | Page 27 of 35

Psychedelics News

Industry

19 May 2022

MindMed Releases Phase 1 Trial Results For Opioid Addiction

MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal...

By Jason Najum

Industry

18 May 2022

Albert Labs Granted Health Canada Licence

Albert Labs has been issued a Health Canada License enabling the possession, production, and delivery of psilocybin and other psychoactive controlled substances...

By Microdose NewsDesk

Industry, Law & Politics

16 May 2022

Numinus Receives Health Canada Approval For Psilocybin Treatment

Although still mired in red tape and the whims of bureaucratic decisions, Numinus has been approved to provide psilocybin psychotherapy under the Special Access Program....

By Jason Najum

Industry

12 May 2022

Field Trip and Nue Life To Bring Psychedelic Therapy Home

Field Trip at Home™ Powered by Nue Life, was announced this morning, a partnership that provides ketamine treatments from the comfort of a person’s home....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry, Science

10 May 2022

Psychedelics and the State of Mental Health

The final path is yet to be determined, but it seems increasingly clear that psychedelic medicine will play a significant role in the future of mental health....

By Ritika Dubey

Industry

10 May 2022

COMPASS Pathways to Fund Study of Psilocybin for Autism

COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults...

By Microdose NewsDesk

Industry

6 May 2022

Wesana Plans to Sell Clinics, Focus on Drug Development

Looks like Wesana's positive meeting with the FDA regarding their lead compound has prompted a revised company game plan...

By Microdose NewsDesk

Industry

5 May 2022

MindBio Therapeutics Completes World’s First Microdosing Trial

MindBio Therapeutics Announces Completion of World First Phase 1 Microdosing Clinical Trial...

By Microdose NewsDesk

Industry

4 May 2022

Optimi Health Granted Amendment To Dealer’s Licence

Optimi Health has received an amendment to its Controlled Substances Dealer’s License, enabling it to further expand the capacity to produce natural, GMP psilocybin...

By Microdose NewsDesk

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result